Benjamin Ory

Associate Professor
Pathophysiology of Bone resorption and Therapy of Primary Bone Tumors Laboratory
Nantes University-School of Medicine, INSERM U957
E-mail: Benjamin.Ory@degruyteropen.com
Page: http://www.univ-nantes.fr/ory-b/1/fiche___annuaireksup/&RH=INSTITUTIONNEL_ENG
http://degruyteropen.com/oncom/

Fields of interest: 

Role of the microRNAs in the metastatic dissemination and chemotherapy sensitivity: Implication of the p53 protein family

Recent publications:

Ory B, Ellisen LW:
A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity.
Oncotarget. 2:259-264 (2011)

Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rothenberg MS, Rocco JW, Ellisen LW:
A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma,
J Clin Invest. 121:809-20 (2011)

Vadysirisack D, Baenke F, Ory B, Lei K, Ellisen LW:
Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response.
Mol Cell Biol. Sept 6, (2011)

Ramsey MR, He L, Forster N, Ory B, Ellisen LW:
Physical Association of HDAC1 and HDAC2 with p63 Mediates Transcriptional Repression and Tumor Maintenance in Squamous Cell Carcinoma.
Cancer Res. Jul 1;71(13):4373-9 (2011)

MoriceauG, Ory B, Mitrofan L, Riganti C, BlanchardF, Brion R, CharrierC, Battaglia S, Pilet P, Denis M, Shultz LD, Mönkkönen J, Rédini F, HeymannD:
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of Ras.
Cancer Res.70(24):10329-39 (2010)

Ory B, Moriceau G, Rédini F, Rogers M.J, Heymann D:
Zoledronic acid resistance mechanisms of osteosarcoma cell lines.
J Cell Mol Med. 12 (3): 928-941 (2008)

Ory B, Blanchard F, Battaglia S, Gouin F, Redini F, Heymann D:
Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
Mol Pharmacol 2007, 71: 333-343 (2007)